Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants

This cohort study investigates whether MUC16 variation could be a useful biomarker for immune checkpoint inhibitor (ICI) therapy.

Detalles Bibliográficos
Autores principales: Yu, Yunfang, Lin, Dagui, Li, Anlin, Chen, Yongjian, Ou, Qiyun, Hu, Hai, Yao, Herui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292997/
https://www.ncbi.nlm.nih.gov/pubmed/32530468
http://dx.doi.org/10.1001/jamanetworkopen.2020.5837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292997/
https://www.ncbi.nlm.nih.gov/pubmed/32530468
http://dx.doi.org/10.1001/jamanetworkopen.2020.5837

Ejemplares similares